|
 |
RebetolThis page contains recent news articles, when available, and an overview of Rebetol but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Rebetol (when available) Ribavirin is an anti-viral drug active against a number of DNA and RNA viruses. It is a member of the nucleoside antimetabolite drugs that interfere with duplication of the viral genetic material. The drug inhibits the activity of the enzyme RNA dependent RNA polymerase, due to it's resemblence to building blocks of the RNA molecules. The oral form is used in the treatment of hepatitis C, in combination with interferon drugs. The aerosol form is used to treat respiratory syncytial virus-related diseases in children. The primary serious adverse effect of ribavirin is hemolytic anemia, which may worsen preexisting cardiac disease. For the treatment of chronic hepatitis C and for respiratory syncytial virus (RSV) Mechanism Of Action: Ribavirin is readily phosphorylated intracellularly by adenosine kinase to ribavirin mono-, di-, and triphosphate metabolites. Ribavirin triphosphate (RTP) is a potent competitive inhibitor of inosine monophosphate (IMP) dehydrogenase, viral RNA polymerase and messenger RNA (mRNA) guanylyltransferase (viral). Guanylyltranserase inhibition stops the capping of mRNA . These diverse effects result in a marked reduction of intracellular guanosine triphosphate (GTP) pools and inhibition of viral RNA and protein synthesis. Ribavirin is also incorporated into the viral genome causing lethal mutagenesis and a subsequent decrease in specific viral infectivity. News Articles on Ribavirin Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518 ... - Nov 2, 2009 The study includes two treatment arms in which patients receive a 4-week lead-in of PEGINTRON and REBETOL prior to receiving narlaprevir 200 mg or 400 mg ... Reuters Schering-Plough reports encouraging results from Phase IIa hepatitis study - Nov 4, 2009 In the lead-in arms of the study, in which patients received a four-week lead-in of Pegintron and Rebetol followed by the addition of narlaprevir, ... Trading Markets (press release) AASLD: Treating Before Transplant Cuts HCV Recurrence - Nov 6, 2009 ...a course of pegylated interferon and ribavirin (Rebetol) before liver transplant may help them avoid recurrence of infection, a researcher said here. ... MedPage Today Vertex pitches hepatitis drug to key doctors - Nov 1, 2009 Consalvo said his company markets a combination of two drugs, PegIntron and Rebetol, as interferon treatments for hepatitis C, competing with Swiss drug ... Boston Globe Aurobindo Pharma pares early losses on US nod for generic drug - Nov 11, 2009 Ribavirin tablet is the generic Copegus and Ribavirin Capsules is generic equivalent to Rebetol of Schering Corporation. Ribavirin tablets and capsules are ... India Infoline.com AASLD: New Drug Boosts HCV Clearance - Nov 3, 2009 ...weeks of pegylated interferon-alfa-2b (PEGIntron) and ribavirin (Rebetol) in a Phase II trial, said Paul Kwo, MD, of Indiana University in Indianapolis. ... MedPage Today US nod for generic drug boosts Aurobindo Pharma - Nov 5, 2009 Ribavirin tablet is the generic Copegus and Ribavirin Capsules is generic equivalent to Rebetol of Schering Corporation. Ribavirin tablets and capsules are ... India Infoline.com UPDATE 1-FDA concerns remain over new use for Schering drug - Oct 30, 2009 WASHINGTON, Oct 30 (Reuters) - The US Food and Drug Administration has "outstanding concerns" about Schering-Plough Corp's (SGP. ... Reuters Schering-Plough Reports Financial Results for 2009 Third Quarter - Oct 22, 2009 NUVARING 131 118 11% 375 330 14% CLARITIN Rx 95 87 9% 323 326 (1%) AVELOX 70 65 7% 250 274 (9%) INTEGRILIN 74 84 (12%) 223 236 (5%) REBETOL 64 63 1% 197 ... Reuters La tua opinione è importante - Nov 11, 2009 ...o Peg-IFN alfa2b (PegIntron®) e ribavirina (Rebetol®) nel trattamento di pazienti naive (mai trattati) con infezione cronica da HCV genotipo 1. ... Associazione EpaC Onlus Schering-Plough's Pegintron and Rebetol combination therapy approved ... - Nov 15, 2007 KENILWORTH, NJ (Thomson Financial) - Schering-Plough Corp said the European Commission last month approved its 48-week standard-dose Pegintron and Rebetol ... Forbes Schering-Plough: FDA OKs label revisions for Pengintron, Rebetol … - Mar 27, 2008 Thursday said the Food and Drug Administration has approved label revisions for Pengintron and Rebetol combination therapy for the treatment of chronic ... Forbes … Approval Of PEGINTRON(TM) And REBETOL(R) Combination Therapy … - Dec 13, 2008 The anemia associated with REBETOL therapy may result in a worsening of cardiac disease. Ribavirin is genotoxic and mutagenic and should be considered a ... Medical News Today - Medical News Today (press release) … Hepatitis C Treatment, Peg-Intron(R) And Rebetol(R) Approved In... - Dec 28, 2005 Schering-Plough Corporation (NYSE: SGP) announced that Schering-Plough KK, the company's country operations in Japan, has received marketing approval for a ... Medical News Today - Medical News Today (press release) Results of PEG-INTRON(R) and REBETOL(R) Study in Retreating … - Oct 27, 2006 BOSTON, Oct. 27 /PRNewswire-FirstCall/ -- Schering-Plough today reported data from EPIC3, a large ongoing clinical study, showing that retreatment with ... RedOrbit Schering-Plough hepatitis combo gets OK EU opinion - Sep 24, 2007 Peg-Intron is approved in the United States as a single agent treatment and for use in combination with Rebetol. Schering-Plough said it tested the ... Reuters … Course of PEG-INTRON(R) and REBETOL(R) Combination Therapy … - May 10, 2005 KENILWORTH, NJ, Oct. 5 /PRNewswire-FirstCall/ -- Schering-Plough Corporation today announced that the European Commission has approved revised dosing ... Euro am Sonntag PEG-INTRON(R) and REBETOL(R) Combination Therapy Demonstrates … - Nov 12, 2005 SAN FRANCISCO, Nov. 12 /PRNewswire-FirstCall/ -- Patients with chronic hepatitis C treated with PEG-INTRON(R) (peginterferon alfa-2b) and REBETOL(R) ... RedOrbit Pegintron(TM) Plus Weight-Based Rebetol(R) Resulted In Higher SVR … - Mar 28, 2008 Schering-Plough Corporation (NYSE: SGP) reported that the US Food and Drug Administration (FDA) has approved label revisions for PEGINTRON(TM) ... Medical News Today - Medical News Today (press release) Pegintron and Rebetol Combination Therapy Approved in EU - Jun 26, 2007 Schering-Plough announced that the European Commission (EC) approved Pegintron and Rebetol combination therapy for previously untreated chronic hepatitis C ... FDA news - FDA news (subscription) Schering-Plough Announces PEG-Intron and Rebetol Approved in Japan … - Dec 22, 2005 KENILWORTH, NJ -- December 22, 2005 -- Schering-Plough Corporation today announced that Schering-Plough KK, the company's country operations in Japan, ... DG News Press Release: Results of PEG-INTRON(R) and REBETOL(R) Study in … - Oct 27, 2006 Results of PEG-INTRON(R) and REBETOL(R) Study in Retreating Hepatitis C Patients Who Failed Previous Combination Therapy Presented at AASLD. from PR ... Pay-Per-View - PR Newswire - HighBeam Research … Efficacy of Shorter PEG-Intron and Rebetol Regimen in Hepatitis C ... - Apr 28, 2006 In the weight- based Rebetol dosing arms, the rate of sustained virologic response ... PEG-Intron and Rebetol are registered trademarks of Schering-Plough. ... DG News … Release: PEGINTRON(TM) and REBETOL(R) Combination Therapy … - Jun 25, 2007 PEGINTRON(TM) and REBETOL(R) Combination Therapy Approved in European Union for Treating Hepatitis C in Patients Coinfected With HIV. from PR Newswire. Pay-Per-View - PR Newswire - HighBeam Research … Course of PEGINTRON(R) and REBETOL(R) Combination Therapy - Aug 1, 2005 PEGINTRON and REBETOL combination therapy was previously approved in the EU for ... "The important results of this clinical study with PEGINTRON and REBETOL ... Medical News Today - Medical News Today (press release) Interim Results From Boceprevir Phase II Study In Genotype 1 Treatment... - Apr 27, 2008 For patients receiving 4 weeks of PEGINTRON and REBETOL therapy prior to the ... The anemia associated with REBETOL therapy may result in a worsening of ... Medical News Today - Medical News Today (press release) … Opinion on PEGINTRON(Tm) and REBETOL(R) Combination Therapy for … - Apr 30, 2007 The CHMP recommendation for approval of PEGINTRON and REBETOL combination ... PEGINTRON and REBETOL combination therapy for chronic hepatitis C was approved ... RedOrbit … Course of Peg-Intron and Rebetol Combination Therapy Approved in … - Oct 5, 2005 KENILWORTH, NJ -- October 5, 2005 -- Schering-Plough Corporation today announced that the European Commission has approved revised dosing instructions ... DG News Schering-Plough Initiates PEG-INTRON(R) Maintenance Study In Patients... - Jan 16, 2006 Anemia associated with REBETOL therapy may exacerbate cardiac disease that ... REBETOL and combination REBETOL/PEG-INTRON therapy must not be used by women ... Medical News Today - Medical News Today (press release) Schering-Plough Reports Top-Line Results of the IDEAL Study. - Jan 14, 2008 Also, fewer of these patients treated with PEGINTRON and REBETOL ... The anemia associated with REBETOL therapy may result in a worsening of cardiac disease ... Free with registration - PR Newswire - AccessMyLibrary.com Schering-Plough Initiates PEG-INTRON 'PROTECT' Study in Liver … - May 23, 2006 Anemia associated with REBETOL therapy may exacerbate cardiac disease that ... REBETOL and combination REBETOL/PEG-INTRON therapy must not be used by women ... Free with registration - PR Newswire - AccessMyLibrary.com Press Release: Pegintron(TM) Plus Weight-Based Rebetol(R) Resulted in... - Mar 27, 2008 Pegintron(TM) Plus Weight-Based Rebetol(R) Resulted in Higher SVR Than Flat Dosing; Low Relapse Rates in Patients With Chronic Hepatitis C. from PR Newswire ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: PEG-INTRON(R) and REBETOL(R) Combination Therapy … - Nov 12, 2005 PEG-INTRON(R) and REBETOL(R) Combination Therapy Demonstrates Consistently High Response Rates Across Patient Weight Groups in 'Real-Life' Treatment ... Pay-Per-View - PR Newswire - HighBeam Research Older HCV Patients Have Tough Time with Combination Therapy - Jan 9, 2006 Patients also received Rebetol in a dose of 600 mg to 800 mg daily. Patients who weighed less than 60 kg received six million units of Intron A and 600 mg ... MedPage Today Pegintron plus Rebetol achieves consistent SVR. - Nov 12, 2007 At the 58th annual meeting of the American Association for the Study of Liver Diseases, held in Boston, Massachusetts, US drug major Schering-Plough ... Free with registration - Pharma Marketletter - AccessMyLibrary.com Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment... - Apr 26, 2008 For patients receiving 4 weeks of PEGINTRON and REBETOL therapy prior to the addition of boceprevir, SVR 12 was 57 percent (59/103), compared to 55 percent ... Genetic Engineering News - Genetic Engineering News (press release) … in Japan for Use in Combination with REBETOL for Chronic Hepatitis... - Jan 7, 2005 PEG-INTRON and REBETOL combination therapy is the first and only ... PEG-INTRON is administered once weekly in combination with REBETOL daily for 48 weeks. ... businesswire.com EU Label Change for Intron A (Interferon Alfa-2b) Incorporates Long... - Apr 26, 2006 Anemia associated with Rebetol therapy may exacerbate cardiac disease that ... Rebetol and combination Rebetol/PEG-Intron therapy must not be used by women ... DG News International Approvals: DCVax-Brain, PegIntron/Rebetol, Revlimid - Jul 16, 2007 July 16, 2007 — The Swiss Institute of Public Health has approved the world's first brain cancer vaccine. The European Commission (EC) has approved an ... Medscape … Trial in US Patients Shows Weight-Based REBETOL in Combination... - Nov 14, 2005 These results from WIN-R (Weight-Based Dosing of PEG-INTRON and REBETOL), ... PEG-INTRON and REBETOL are registered trademarks of Schering-Plough. ... Web Services Journal - Web Services Journal … Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy … - Dec 12, 2008 Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C. from PR Newswire. Pay-Per-View - PR Newswire - HighBeam Research Schering-Plough Announces Hepatitis C Data Presentations at Digestive... - May 18, 2006 Anemia associated with REBETOL therapy may exacerbate cardiac disease that ... REBETOL and combination REBETOL/PEG-INTRON therapy must not be used by women ... Free with registration - PR Newswire - AccessMyLibrary.com SP's Pegintron plus Rebetol gets expanded indication. - Jul 9, 2007 The European Commission has approved US drug major Schering-Plough's Pegintron (peginterferon alfa-2b, 1.5mcg/kg once-weekly) and Rebetol (ribavirin, ... Free with registration - Pharma Marketletter - AccessMyLibrary.com … Course of PEG-INTRON(R) and REBETOL(R) Combination Therapy … - Oct 5, 2005 Shorter Course of PEG-INTRON(R) and REBETOL(R) Combination Therapy Approved in European Union for Certain Hepatitis C Patients With Genotype 1 and Low Viral ... Pay-Per-View - PR Newswire - HighBeam Research FDA Safety Changes: Keppra, Naropin, Rebetol - Dec 22, 2006 December 22, 2006 — The US Food and Drug Administration (FDA) has approved safety label revisions to advise of the expected similarity of levetiracetam's ... Medscape Press Release: PEGINTRON(TM) and REBETOL(R) Approved in … - Nov 15, 2007 PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon ... Pay-Per-View - PR Newswire - HighBeam Research AASLD: Weight-Based Dosing of Rebetol Improves Outlook for HCV - Nov 17, 2005 By Michael Smith,. SAN FRANCISCO, Nov. 17 - Giving Rebetol (ribavirin) based on the weight of a chronic hepatitis C (HCV) patient, rather than a flat dose, ... MedPage Today FDA Grants Fast Track Designation To Oral HCV Protease Inhibitor SCH ... - Jan 30, 2006 Anemia associated with REBETOL therapy may exacerbate cardiac disease that ... REBETOL and combination REBETOL/PEG-INTRON therapy must not be used by women ... Medical News Today - Medical News Today (press release) PEGINTRON(TM) Approved In China For Treating Chronic Hepatitis B - Apr 8, 2007 Anemia associated with REBETOL therapy may exacerbate cardiac disease that ... REBETOL and combination REBETOL/PEGINTRON therapy must not be used by women ... Medical News Today - Medical News Today (press release) USA pharma: Pegintron/Rebetol approved in children - Dec 17, 2008 US drug major Schering-Plough has received marketing approval from the US Food and Drug Administration for a combination of Pegintron (peginterferon ... $34.00 - EIU Country Analysis - Alacra Store … ; Study finds PegIntron and Rebetol achieved sustained virological ... - Jan 11, 2005 ..."PegIntron and Rebetol combination therapy previously has been shown ... Schering-Plough supplied the PegIntron, Intron A and Rebetol used in the study. ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Initial Results of Phase II Study with HCV Protease Inhibitor... - Oct 18, 2007 Boceprevir is being evaluated in combination with PEGINTRON and REBETOL for the treatment of patients chronically infected with hepatitis C virus (HCV) ... Free with registration - PR Newswire - AccessMyLibrary.com … ; Study finds PegIntron and Rebetol achieved sustained virological ... - Jan 14, 2005 ..."PegIntron and Rebetol combination therapy previously has been shown ... Schering-Plough supplied the PegIntron, Intron A and Rebetol used in the study. ... Pay-Per-View - Drug Week - Factiva, from Dow Jones Boceprevir Phase II Study Showed High Rate of Sustained Response … - Nov 1, 2008 These results compared to a 38 percent SVR rate (SVR 12) for patients in the control group receiving 48-weeks of PEGINTRON and REBETOL alone (ITT).(2-4) ... International Business Times Combination of PEG-INTRON and REBETOL effective for HCV: Schering- … - Dec 4, 2006 According to Schering-Plough, chronic hepatitis patients who are treated with a combination of PEG-INTRON (peginterferon alfa -2a) and REBETOL (ribavirin) ... Pay-Per-View - Pharma Japan - Factiva, from Dow Jones Initial Results Of Phase II Study With HCV Protease Inhibitor... - Oct 19, 2007 Boceprevir is being evaluated in combination with PEGINTRON and REBETOL for the treatment of patients chronically infected with hepatitis C virus (HCV) ... Medical News Today - Medical News Today (press release) International Approvals: Remicade, Vasovist, Peg-Intron, Rebetol - Oct 10, 2005 Oct. 10, 2005 — The European Commission has approved infliximab injection for the treatment of moderate to severe plaque psoriasis in patients who are ... Medscape Press Release: Final Results of Ideal Study Presented at Annual... - Apr 26, 2008 Article: PEGINTRON and REBETOL Recommended for Approval as ... ... Plough Spain. "PegIntron and Rebetol combination therapy is just one example ... ... Pay-Per-View - PR Newswire - HighBeam Research Vertex Pharmaceuticals (VRTX) Falls On Positive Data From Competing … - Oct 18, 2007 Schering-Plough's drug, in combination with PEGINTRON and REBETOL, showed a response of 79% after 12 weeks of treatment. Schering-Plough called the response ... StreetInsider.com - StreetInsider.com (subscription) Press Release: PEG-INTRON(R) and REBETOL(R) Combination Therapy … - Nov 12, 2005 PEG-INTRON(R) and REBETOL(R) Combination Therapy Demonstrates Consistently High Response Rates Across Patient Weight Groups in 'Real-Life' Treatment ... Pay-Per-View - PR Newswire Europe - HighBeam Research Boceprevir Phase II Study Showed High Rate of Sustained Response … - Jan 11, 2008 These results compared to a 38 percent SVR rate (SVR 12) for patients in the control group receiving 48-weeks of PEGINTRON and REBETOL alone (ITT).(2-4) ... FinanzNachrichten.de … Opinion on PEGINTRON(Tm) and REBETOL(R) Combination Therap - Apr 30, 2007 ..."PegIntron and Rebetol combination therapy is just one example . ... In addition to examining the ability of PegIntron and Rebetol to achieve ... studies in ... Pay-Per-View - PR Newswire - HighBeam Research Invasive Fungal Infections - CHMP Adopts Positive Opinion for... - Aug 1, 2005 There are no guarantees about the market performance of PEG-INTRON and REBETOL combination therapy, Schering-Plough stock or Schering-Plough's business. ... Medical News Today - Medical News Today (press release) … With PegIntron and Rebetol Combination Therapy Demonstrated in... - Apr 18, 2005 Clinical Benefits of Retreatment With PegIntron and Rebetol Combination Therapy Demonstrated in Difficult-to-Treat Hepatitis C Patients. ... find PR ... Pay-Per-View - PR Newswire Europe - HighBeam Research … With PegIntron and Rebetol Combination Therapy Demonstrated in - Apr 18, 2005 Clinical Benefits of Retreatment With PegIntron and Rebetol Combination Therapy Demonstrated in Difficult-to-Treat Hepatitis C Patients; PegIntron Achieves ... Pay-Per-View - PR Newswire - HighBeam Research … For Shorter Course of PEGINTRON(R) and REBETOL(R) Combination T - Jul 29, 2005 PEGINTRON and REBETOL combination therapy was previously approved in the EU for ... "The important results of this clinical study with PEGINTRON and REBETOL ... RedOrbit … Opinion on PEGINTRON(TM) and REBETOL(R) Combination Therap - Apr 30, 2007 PEGINTRON and REBETOL Combination Therapy PEGINTRON and REBETOL combination ... dose in ... Article: New Study Reports Results of PegIntron and Rebetol ... ... Pay-Per-View - PR Newswire Europe - HighBeam Research … -Plough Announces PEG-INTRON(R) and REBETOL(R) Approved in … - Dec 22, 2005 Schering-Plough Announces PEG-INTRON(R) and REBETOL(R) Approved in Japan for Expanded Use in Treating Chronic Hepatitis C. from PR Newswire Europe. Pay-Per-View - PR Newswire Europe - HighBeam Research … : Data on PEG-INTRON(R) and REBETOL(R) Combination Therapy in … - May 12, 2005 Data on PEG-INTRON(R) and REBETOL(R) Combination Therapy in Diverse Patient Populations to Be Presented at 2005 Digestive Disease Week (DDW) Meeting. from ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Positive results from Visudyne(R) combination therapy ... - Mar 28, 2008 INTRON and REBETOL combination therapy trial, the incidence ... INTRON/REBETOL groups was similar to ... INTRON A/REBETOL group. In many but . ... Pay-Per-View - PR Newswire - HighBeam Research Weight-based Dosage Increases Hepatitis C Treatment Efficacy - Dec 28, 2007 The study of over 5000 patients with hepatitis C virus (HCV) showed that the treatment with weight-based REBETOL (ribavirin, USP) (RBV) in combination with ... MedIndia … recommendations for SP's PEG-Intron and Rebetol by CHMP.(Committee... - Aug 8, 2005 The European Union's Committee for Medicinal Products for Human Use has issued a positive opinion recommending approval of revised dosing instructions which ... $4.95 - Pharma Marketletter - ECNext PegIntron/Rebetol in HCV: positive data.(pharmaceutical industry)(Brie... - Apr 25, 2005 Interim results from the ongoing EPIC (Evaluation of PegIntron in Control of Hepatitis C Cirrhosis) clinical study, presented at the European Association ... $4.95 - Pharma Marketletter - ECNext … Commission approves shorter Pegintron+Rebetol combo therapy.(Brief... - Oct 10, 2005 US drug major Schering-Plough says that the European Commission has approved revised dosing instructions allowing for a shorter, 24-week course of Pegintron ... Pay-Per-View - Pharma Marketletter - Factiva, from Dow Jones Cholesterol drugs boost Schering-Plough - May 1, 2005 ...drugs and renewed vigour in Schering's older drugs all but one of them, hepatitis C treatment Rebetol, reporting first quarter sales increases. ... Pharmafocus Schering-Plough Announces Hepatitis C Data Presentations At Digestive... - May 19, 2007 Anemia associated with REBETOL therapy may exacerbate cardiac disease that ... REBETOL and combination REBETOL/PEGINTRON therapy must not be used by women ... Medical News Today - Medical News Today (press release) Press Release: European Union's CHMP Issues Positive Opinion on … - Sep 24, 2007 PEGINTRON and REBETOL(R) will be the only available hepatitis C therapy ... Upon European Commission approval, PEGINTRON and REBETOL will be the only ... Pay-Per-View - PR Newswire - HighBeam Research … Positive Opinion for Shorter Course of PEGINTRON(R) and REBETOL(R) - Jul 29, 2005 PEGINTRON and REBETOL combination therapy was previously approved in the EU for ... "The important results of this clinical study with PEGINTRON and REBETOL ... Pay-Per-View - PR Newswire Europe - HighBeam Research Schering-Plough Announces Hepatitis C Data Presentations at Digestive... - May 18, 2007 Anemia associated with REBETOL therapy may exacerbate cardiac disease that ... REBETOL and combination REBETOL/PEGINTRON therapy must not be used by women ... Free with registration - PR Newswire - AccessMyLibrary.com Livers Under Wrap: AASLD 2005 - Nov 25, 2005 The patients received consensus interferon at 15 mcg daily plus Rebetol at 11 mg/kg/day, with treatment planned to last for 48 weeks. ... MedPage Today REGULATORY NEWS IN BRIEF - Jun 13, 2005 Pegintron is the first peginterferon preparation in Japan approved for combination therapy with Rebetol. It was launched last December after being approved ... Pay-Per-View - Pharma Japan - Factiva, from Dow Jones Schering-Plough Provides Update on Boceprevir Clinical Development … - Nov 24, 2008 The anemia associated with REBETOL therapy may result in a worsening of cardiac disease. Ribavirin is genotoxic and mutagenic and should be considered a ... International Business Times Schering-Plough Initiates PEG-INTRON(R) Maintenance Study in Patients... - Jan 13, 2006 Anemia associated with REBETOL therapy may exacerbate cardiac disease that ... REBETOL and combination REBETOL/PEG-INTRON therapy must not be used by women ... biotech-intelligence.com New Data Evaluating 'Real World' Treatment Results With PEGINTRON(R … - Apr 15, 2005 About PEGINTRON and REBETOL Combination Therapy PEGINTRON and REBETOL combination ... Treatment with PegIntron and Rebetol ... with Genotype 1 Chronic ... Pay-Per-View - PR Newswire Europe - HighBeam Research Press Release: Top-Line Results of Boceprevir Phase II Study Showed … - Aug 4, 2008 Importantly, for patients who received the PEGINTRON and REBETOL lead in and had ... Article: PEGINTRON(TM) and REBETOL(R) Combination Therapy Approved ... ... Pay-Per-View - PR Newswire - HighBeam Research First large head-to-head comparison of Schering and Roche HCV … - Jan 16, 2008 The standard daily dose of Rebetol is 800mg, although studies have suggested that ... (1) PegIntron 1.5mcg/kg/week (the standard dose) plus Rebetol, ... Aidsmap CHMP Issues Positive Opinion On PEGINTRON For Retreating Hepatitis … - Sep 25, 2007 Upon European Commission approval, PEGINTRON and REBETOL will be the only ... PEGINTRON and REBETOL combination therapy for chronic hepatitis C was approved ... emaxhealth.com Press Release: Schering-Plough To Initiate Phase III Studies With HCV... - May 21, 2008 ..."We are excited to advance to Phase III clinical studies with boceprevir in combination with PEGINTRON and REBETOL," said Fred Poordad, M.D., ... Pay-Per-View - PR Newswire - HighBeam Research Results of Peginterferon Alfa-2b and Ribavirin Study in Retreating … - Oct 30, 2006 ..."The results of this study demonstrate that retreatment with PEG-Intron and Rebetol combination therapy may help address this unmet medical need in this ... DG News Press Release: PEGINTRON(TM) Approved in China for Treating Chronic … - Apr 5, 2007 PEGINTRON and REBETOL were ... patients with chronic hepatitis C alone. "Effective ... HCV genotype. PEGINTRON in the European Union PEGINTRON and REBETOL ... Pay-Per-View - PR Newswire - HighBeam Research A press release distributed by PR Newswire Europe - Apr 18, 2005 ..."Our research demonstrates that this difficult-to-treat patient group can be successfully retreated with PegIntron and Rebetol combination therapy." ... prnewswire.co.uk Press Release: Schering-Plough Highlights PEGINTRON(TM) and … - Apr 17, 2008 Article: PEGINTRON(TM) and REBETOL(R) Combination Therapy ... ... Powder for Injection for use in combination therapy with REBETOL(R) (ribavirin ... only ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Boceprevir Phase II Study Showed High Rate of … - Nov 1, 2008 Article: PEGINTRON(TM) and REBETOL(R) Combination Therapy Approved . ... The study showed that PEGINTRON (1.5 mcg/kg once weekly) and REBETOL ... virologic ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Has added Schering-Plough Corp. to their watch list. -... - Jan 15, 2008 Powder for Injection for use in combination therapy with Rebetol ... "Peg-Intron and Rebetol combination therapy gives new hope to some of the estimated . ... Pay-Per-View - M2 Presswire - HighBeam Research … von kürzerer PEG-INTRON- und REBETOL-Therapie bei Hepatitis C- … - Apr 28, 2006 Im gewichtsbasierten REBETOL-Dosierungsarm betrug die Rate der anhaltenden ... PEG-INTRON und REBETOL sind eingetragene Markenzeichen von Schering-Plough. ... presseportal.de Press Release: Initial Results of Phase II Study with HCV Protease … - Oct 18, 2007 Article: PEGINTRON and REBETOL Recommended for Approval as ... ... 79% In clinical studies, the combination of PEGINTRON and REBETOL had ... ... Pay-Per-View - PR Newswire - HighBeam Research … para la terapia de combinación PEGINTRON(TM) y REBETOL(R) para la ... - Apr 30, 2007 La terapia de combinación de PEGINTRON y REBETOL para la hepatitis C crónica recibió la autorización de comercialización en la UE en marzo de 2001. ... elEconomista.es … mit PegIntron und Rebetol Kombinationstherapie bei schwer zu - Apr 18, 2005 ..."Unsere Forschung zeigt, dass diese Gruppe von schwer zu behandelnden Patienten erfolgreich mit der PegIntron und Rebetol Kombinationstherapie ... presseportal.de … .- La terapia de 'PegIntron' más 'Rebetol' (Schering-Plough),... - Jun 23, 2008 La terapia individualizada de peginterferón alfa-2b y ribavirina, comercializado por Schering-Plough como 'PegIntron' y 'Rebetol' respectivamente, ... ecodiario Modifiche AIC in GU: Pegintron, Rebetol - May 16, 2008 ...pazienti in cui un precedente trattamento di combinazione con interferone alfa (pegilato o nonpegilato) e ribavirina o la monoterapia con interferone alfa ... Pillole.org DDW: Novel HCV Protease Inhibitor Promising in Early Trial - May 24, 2006 The 12 patients were continued on weight-based Rebetol therapy for 12 weeks. ... That patient is being continued on Pegysys and Rebetol. ... MedPage Today COMUNICADO: Schering-Plough consigue grandes avances en el … - Apr 11, 2007 Entre ellas están varios estudios de la terapia de combinación PEGINTRON(R) (peginterferon alfa-2b) y REBETOL(R) (ribavirina), un método estándar de cuidado ... elEconomista.es DDW: Relapsed HCV Patients Achieve Sustained Response with 72- … - May 22, 2006 LOS ANGELES, May 22 — Daily consensus interferon plus Rebetol (ribavirin) for 72 weeks ... Patients in both treatment arms received weight-based Rebetol. ... MedPage Today Meeting Highlights From The Committee For Medicinal Products For … - Apr 23, 2007 Rebetol must be used in combination with peginterferon alfa-2b in this indication. ... As Rebetol, also from Schering Plough Europe, is used in combination ... Medical News Today - Medical News Today (press release) Press Release: Largest US Hepatitis C Trial Provides Insight Into … - May 24, 2006 In the weight-based REBETOL dosing arms, the SVR rate was 68 percent for the ... Article: Clinical Benefits of Retreatment With PegIntron and Rebetol ... ... Pay-Per-View - PR Newswire - HighBeam Research Article: Adalimumab looks good for psoriasis.(Skin Disorders) -... - Jun 1, 2005 INTRON and REBETOL combination therapy in all HCV virus ... effectiveness of ... Article: Clinical Benefits of Retreatment With PegIntron and Rebetol ... ... Pay-Per-View - Family Practice News - HighBeam Research Schering-Plough's 3rd-Qtr Profit More Than Tripled - Oct 24, 2005 Schering-Plough introduced its Peg-Intron and Rebetol hepatitis drugs in Japan ... The December 2004 introduction into Japan of the Peg-Intron and Rebetol ... Bloomberg Press Release: Schering-Plough Corp. Review in Progress. - M2 … - Apr 18, 2008 Schering-Plough Corp. was in the red less than ... REBETOL (ribavirin, USP) combination therapy vs. Pegasys (peginterferon ... ... Pay-Per-View - M2 Presswire - HighBeam Research Hepatitis; PEG-INTRON is now available in Japan for hepatitis C … - Jan 14, 2005 PEG-INTRON and REBETOL are marketed worldwide by Schering-Plough Corporation (NYSE: SGP). PEG-INTRON and REBETOL combination therapy is the first and only ... Pay-Per-View - Genomics & Genetics Weekly - Factiva, from Dow Jones … la UE la terapia de combinación PEGINTRON(TM) y REBETOL(R) para la … - Jun 25, 2007 PEGINTRON y REBETOL fueron aprobados anteriormente en la UE para el ... La terapia de combinación de PEGINTRON y REBETOL para la hepatitis C crónica fue ... elEconomista.es Brand Names/Synonyms: Rebetol is also known by the following brand names and/or synonymsBiopolymers; Copegus; DRG-0028; HSDB 6513; ICN 1229; ICN-1229; RBV; RIBAV; RTC; RTCA; RTP; Rebetol; Rebetron; Rebretron; Ribamide; Ribamidil; Ribamidyl; Ribasphere; Ribavirin; Ribavirin Capsules; Ribavirin Triphosphate; Ribavirin [Usan:Inn]; Ribavirin-Tp; Ribavirina [Inn-Spanish]; Ribavirine; Ribavirine [Inn-French]; Ribavirinum [Inn-Latin]; Tribavirin; Varazid; Vilona; Viramid; Virazid; Virazole; Virazole 5'-Triphosphate Drug Category: Rebetol is categorized under the following by the FDA: Antiviral; ATC:J05AB04 Dosage Forms: Inhalation solution, Tablets Absorption: Ribavirin was rapidly and extensively absorbed following oral administration. However, due to first-pass metabolism, the absolute bioavailability averaged 64% (44%). Interactions: [an error occurred while processing this directive] Chemical IUPAC Name: 1-[3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1H-1,2,4-triazole-3-carboxamide |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |
